Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a "real-world" setting

Authors

• Sean E Smith, Washington University School of Medicine in St. Louis
• Kelly McCoy-Gross, Washington University School of Medicine in St. Louis
• Amber Malcolm, Washington University School of Medicine in St. Louis
• Jeri Oranski, Washington University School of Medicine in St. Louis
• Jesse W Markway, Washington University School of Medicine in St. Louis
• Timothy M Miller, Washington University School of Medicine in St. Louis
• Robert C Bucelli, Washington University School of Medicine in St. Louis

Journal

Annals of Clinical and Translational Neurology

Publication Date

2-1-2025

Volume

12

Issue

2

First Page

311

Last Page

319

Document Type

Open Access Publication

DOI

10.1002/acn3.52264

Rights and Permissions

Smith, S.E., McCoy-Gross, K., Malcolm, A., Oranski, J., Markway, J.W., Miller, T.M. and Bucelli, R.C. (2025), Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a “real-world” setting. Ann Clin Transl Neurol, 12: 311-319. https://doi.org/10.1002/acn3.52264 © 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Recommended Citation

Smith, Sean E; McCoy-Gross, Kelly; Malcolm, Amber; Oranski, Jeri; Markway, Jesse W; Miller, Timothy M; and Bucelli, Robert C, "Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a "real-world" setting." Annals of Clinical and Translational Neurology. 12, 2. 311 - 319. (2025).
https://digitalcommons.wustl.edu/oa_4/6966

Department

ICTS (Institute of Clinical and Translational Sciences)